Loading clinical trials...

A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients | Clinical Trials | Clareo Health

RECRUITINGPHASE2

A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients

A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 As First-Line Treatment in Metastatic Colorectal Cancer Patients

NCT06493760•Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

View on ClinicalTrials.gov

Summary

This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Males and/or females over age 18
•2. Histologically and/or cytologically documented metastatic colorectal cancer confirmed .
•3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
•4. Expected survival \>=12 weeks.
•5. Signed informed consent form.

Exclusion Criteria

•1. Known uncontrolled or symptomatic central nervous system metastatic disease.
•2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \>1 (National Cancer Institute Common terminology Criteria \[NCI CTCAE\] v.5.0).
•3. Inadequate organ or bone marrow function.
•4. Pregnant or breast-feeding woman.
•5. Known allergies, hypersensitivity, or intolerance to SSGJ-707 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Locations (1)

Liu Tianshu

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

September 3, 2024

Primary Completion Date

June 1, 2025

Completion Date

June 1, 2027

Last Updated

September 19, 2024

Enrollment

130

ESTIMATED participants

Conditions

Metastatic Colorectal Cancer

Interventions

SSGJ-707

DRUG

Bevacizumab

DRUG

Oxaliplatin

DRUG

Capecitabine

DRUG

Calcium Folinate

DRUG

5-fluorouracil

DRUG

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068

Advanced CancerMetastatic Cancer+7 more

View study

RECRUITINGPHASE1

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

NCT06625775

Solid Tumor, AdultMetastatic Breast Cancer+9 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 19, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients

Inclusion Criteria

Exclusion Criteria

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer